Related Experiment Video
Updated: May 11, 2026
12:18
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
The mental capacity act and dementia research
1St James' Hospital, Portsmouth. aileen.murray@solent.nhs.uk
Nursing Older People
|May 8, 2013
Summary
Involving people with dementia in research is crucial but challenging. This article guides researchers on ethically applying the Mental Capacity Act 2005 for dementia studies, ensuring participant rights and research integrity.
Area of Science:
- Neuroscience
- Bioethics
- Legal Medicine
Background:
- Meaningful research impact for dementia patients requires their direct involvement in studies.
- Conducting research with individuals who may lack decision-making capacity presents significant ethical and practical hurdles for investigators.
- Ethical research practices are paramount when including vulnerable populations like those with dementia.
Purpose of the Study:
- To explore the practical implementation of the Mental Capacity Act 2005 within research contexts involving individuals with dementia.
- To offer actionable advice for researchers on applying the principles of the Mental Capacity Act 2005 in study design and execution.
- To enhance ethical expertise among researchers aiming to include people with dementia in their studies.
Main Methods:
- Review of the Mental Capacity Act 2005 provisions relevant to research participation.
- Analysis of practical challenges and ethical considerations in obtaining informed consent from individuals with impaired capacity.
- Guidance on navigating regulatory frameworks, including the Integrated Research Application System and NHS research ethics committees.
Main Results:
- The Mental Capacity Act 2005 provides a legal framework for research involving individuals lacking capacity.
- Practical application requires careful assessment of capacity and adherence to safeguarding principles.
- Utilizing resources from the Integrated Research Application System and NHS bodies aids ethical research conduct.
Conclusions:
- Ethical and effective research involving people with dementia is achievable through diligent application of the Mental Capacity Act 2005.
- Researchers must possess a thorough understanding of the Act's practical implications to ensure participant protection and research validity.
- Collaboration with ethics committees and regulatory bodies is essential for navigating the complexities of research with capacity-impaired individuals.
Related Concept Videos
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:30Cognitive Development During Adulthood
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...